Affinity Asset Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Affinity Asset Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-24,692	Closed	-$1.26M	–	108
2025 Q2	$1.26M	Sell	24,692 -25,000	-50%	-$1.11M	0.17%	66
2025 Q1	$2.24M	Sell	49,692 -21,050	-30%	-$992K	0.21%	65
2024 Q4	$2.93M	Sell	70,742 -4,258	-6%	-$177K	0.39%	51
2024 Q3	$2.92M	Sell	75,000 -80,000	-52%	-$3.19M	0.4%	57
2024 Q2	$5.3M	Sell	155,000 -5,000	-3%	-$131K	0.61%	43
2024 Q1	$4.02M	Buy	160,000 +110,000	+220%	+$3.02M	0.5%	59
2023 Q4	$1.48M	Buy	50,000 +20,000	+67%	+$605K	0.27%	62
2023 Q3	$948K	Hold	30,000	–	–	0.27%	63
2023 Q2	$776K	Sell	30,000 -65,000	-68%	-$1.73M	0.27%	57
2023 Q1	$2.28M	Buy	95,000 +55,000	+138%	+$1.25M	0.75%	39
2022 Q4	$780K	Buy	+40,000	New	+$791K	0.31%	53

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Affinity Asset Advisors's MIRM Position: Q3 2025 in Review

Affinity Asset Advisors sold out of Mirum Pharmaceuticals (MIRM) in Q3 2025, closing a stake of 24,692 shares — an estimated $1.26M sold.

Affinity Asset Advisors first reported a position in MIRM in Q4 2022 and held it in 11 quarters. The position peaked at $5.3M in Q2 2024. 272 funds tracked by Wall St. Rank hold MIRM as of Q3 2025.

Affinity Asset Advisors reported no remaining Mirum Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Affinity Asset Advisors sold 24,692 Mirum Pharmaceuticals shares in Q3 2025, an estimated $1.26M.
Affinity Asset Advisors first reported a position in Mirum Pharmaceuticals in Q4 2022 and held it in 11 quarters.
Affinity Asset Advisors's Mirum Pharmaceuticals position peaked at $5.3M in Q2 2024.
272 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2025.

Based on Affinity Asset Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.